Patient and caregiver insights into lung cancer treatment decision-making: an exploratory focus group
Healthcare providers should distribute reliable educational materials and have early conversations with patients on individual lung cancer treatment, health-related quality of life goals, potential AEs, and distinguishing AEs from disease progression symptoms.
Authors
- S. Hutter
- Lisa Shea (ORCID: https://orcid.org/0000-0002-3512-0083)
- Andrew L. Johnson (ORCID: https://orcid.org/0000-0003-3848-6977)
- John B. Holcomb (ORCID: https://orcid.org/0000-0001-8312-9157)
- Julie Vanderpoel (ORCID: https://orcid.org/0000-0001-5055-6216)
- W. Peters (ORCID: https://orcid.org/0009-0008-8969-7524)
- Karen Fixler (ORCID: https://orcid.org/0009-0008-6005-1332)
- Nida Imran (ORCID: https://orcid.org/0009-0005-4629-466X)
Institutions
- Janssen (Belgium) (BE)
- Thermo Fisher Scientific (Sweden) (SE)
- Johnson & Johnson (Israel) (IL)
- Thermo Fisher Scientific (United States) (US)
- Janssen Scientific Affairs (United States)
- Thermo Fisher Scientific (Israel) (IL)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1080/03007995.2025.2456009
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04